Top Markets
#1 Black Phoenix Black Phoenix +822.27%
#2 MiL.k Alliance MiL.k Alliance +25.89%
#3 Beam Beam +25.14%
#4 Tutorial Tutorial +23.75%
#5 SAFEcoin SAFEcoin +19.22%
#6 Bless Bless +18.06%
#7 THORChain THORChain +16.24%
#8 EfficientFrontier EfficientFrontier +14.07%
#9 Biconomy Biconomy +13.52%
#10 Versatize Coin Versatize Coin +12.49%
Coin of the day
Black Phoenix Black Phoenix
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
RayzeBio, Inc. Common Stock RayzeBio, Inc. Common Stock

RayzeBio, Inc. Common Stock

RYZB
Clasificación en acciones #5677
RayzeBio, Inc. is dedicated to creating radiopharmaceutical therapies (RPTs)... RayzeBio, Inc. is dedicated to creating radiopharmaceutical therapies (RPTs) for oncology applications. Its primary therapeutic candidate, RYZ101, is currently advancing through Phase 3 clinical trials for the management of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The company's innovative pipeline also features RYZ801, a distinct peptide engineered to deliver Actinium-225 (Ac225) by targeting GPC3, intended for treating hepatocellular carcinoma (HCC). Additionally, RayzeBio is developing RYZ811, a companion diagnostic imaging agent comprising a peptide binder, a chelator, and Gallium-68 (Ga68). Another active development program involves a novel proprietary small molecule designed to target CA9, delivering Ac225 for potential use against clear cell renal cell carcinoma (ccRCC). The firm was established in 2020 and is headquartered in San Diego, California.
Precio por acción
$62.49
Última sincronización: 2024-03-06
Capitalización bursátil
$2.52B
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
US
Comercio RayzeBio, Inc. Common Stock (RYZB)

Categoría

Healthcare
Ganancias de RayzeBio, Inc. Common Stock (RYZB)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di RayzeBio, Inc. Common Stock, gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de RayzeBio, Inc. Common Stock desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH